Company news

Atossa Therapeutics, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Atossa Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update

November 12, 2023

Atossa Therapeutics Appoints Financial Executive Jonathan Finn to its Board of Directors

November 8, 2023

Atossa to Present at Cantor Fitzgerald Global Healthcare Conference 2023

September 17, 2023

Atossa Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update

August 13, 2023

Atossa Therapeutics to Provide Business Update and Report Second Quarter 2023 Financial Results on August 14, 2023

August 7, 2023

Atossa Therapeutics Receives Approval from Health Canada to Conduct Phase 2 EVANGELINE Clinical Trial in Canada

July 19, 2023

Atossa Therapeutics Provides Enrollment Update for Ongoing Phase 2 Karisma-Endoxifen Clinical Trial

July 9, 2023

Atossa Therapeutics Announces Sponsored Research Agreement with Weill Cornell Medicine to Address Treatment Challenges in Triple Negative Breast Cancer

July 5, 2023

Atossa Therapeutics announces 30% enrollment for Phase 2 I-Spy breast cancer clinical trial

June 27, 2023

Atossa Therapeutics Announces $10M Stock Repurchase Program

June 26, 2023

Atossa Therapeutics Announces Sponsorship of Are You Dense MusicFest 2023

June 21, 2023

Atossa Therapeutics announces further patent protection for Endoxifen

June 20, 2023

Atossa Completes Enrollment of Pharmacokinetic Run-In Cohort in Phase 2 EVANGELINE Clinical Trial Evaluating (Z)-Endoxifen as a Neoadjuvant Treatment for ER+ / HER2- Breast Cancer

June 11, 2023

Atossa Appoints Life Sciences Financial and Operations Industry Veteran Greg Weaver as Chief Financial Officer

May 31, 2023

Atossa Therapeutics Announces First Quarter 2023 Financial Results and Provides Corporate Update

May 14, 2023

Atossa Therapeutics Announces Year-End 2022 Financial Results and Provides Corporate Update

March 21, 2023

Atossa Therapeutics and Quantum Leap Healthcare Announce New Study Arm to Evaluate (Z)-Endoxifen in the Ongoing I-SPY 2 Clinical Trial

March 20, 2023

Atossa Doses First Patient in Phase 2 Neoadjuvant Clinical Study of (Z)-Endoxifen in Premenopausal Women with ER+/HER2- Breast Cancer

February 22, 2023

Atossa Therapeutics Announces the Appointment of Eric Van Zanten as Vice President, Investor and Public Relations

December 6, 2022

Atossa Therapeutics Announces Third Quarter 2022 Financial Results and Provides Corporate Update

November 6, 2022

Atossa Therapeutics, Inc. to Acquire Stake in Privately Held Dynamic Cell Therapies as Part of Overall CAR-T Strategy

October 31, 2022

Atossa Therapeutics, Inc. Announces Appointment of Pharma Industry Veteran Richard Graydon, M.D., Ph.D.

October 24, 2022

Atossa Therapeutics, Inc. Receives Authorization from FDA to Initiate its Phase 2 Study of Neoadjuvant (Z)-endoxifen in Premenopausal Women with ER+/HER2- Breast Cancer

October 23, 2022

Atossa Therapeutics Appoints Dr. Paul Wabnitz to Its Scientific Advisory Board

August 17, 2022

Atossa Therapeutics Announces Second Quarter 2022 Financial Results and Provides Corporate Update

August 7, 2022

Atossa Therapeutics Appoints Biotech Industry Communications Veteran Charles Butler as Vice President, Investor Relations and Public Relations

June 1, 2022

Atossa Therapeutics Announces First Quarter 2022 Financial Results and Provides Corporate Update

May 8, 2022

Atossa Therapeutics Announces Completion of Part B of Clinical Study of AT-H201

April 19, 2022

Atossa Therapeutics Announces Issuance of Key U.S. Patent Covering Endoxifen

March 7, 2022

Atossa Therapeutics Announces Year-End 2021 Financial Results and Provides Corporate Update

February 27, 2022

Atossa Therapeutics President and CEO Dr. Steven C. Quay Issues Annual Letter to Stockholders Highlighting Key Recent Accomplishments and Strategy for 2022

January 26, 2022

Atossa Therapeutics Announces Advancement to Part B of Clinical Study of AT-H201

January 17, 2022

Atossa Therapeutics Begins Enrollment of Phase 2 Clinical Study of Oral Endoxifen in Sweden

December 21, 2021

Atossa Therapeutics Completes Pre-IND Meeting with U.S. Food & Drug Administration

December 5, 2021

Atossa Therapeutics Announces Third Quarter 2021 Financial Results and Provides Corporate Update

November 14, 2021

Atossa Therapeutics Begins Enrollment in Clinical Study of AT-H201 in Australia

September 29, 2021

Atossa Therapeutics Adjourns Special Stockholder Meeting to October 7, 2021 to Allow Additional Time to Vote

September 6, 2021

Atossa Therapeutics Receives Approval from the Swedish Ethics Review Authority to Initiate a Phase 2 Clinical Study of Oral Endoxifen to Reduce Mammographic Breast Density in Sweden

September 1, 2021

Atossa Therapeutics Announces Second Quarter 2021 Financial Results - Provides Corporate Update and Information about Upcoming Stockholder Meeting

August 12, 2021

Atossa Therapeutics Receives Regulatory Approval To Open Clinical Study of AT-H201 in Australia

July 6, 2021

Atossa Therapeutics Receives Approval from Swedish Regulators to Initiate Phase 2 Clinical Study of Oral Endoxifen to Reduce Mammographic Breast Density

June 10, 2021

Atossa Therapeutics Announces Final Data from Phase 2 Endoxifen Breast Cancer Study Primary Endpoint Met: 65.1% Reduction in Biomarker Ki-67; Secondary Endpoint Met: Endoxifen Safe and Well Tolerated

June 8, 2021

Atossa Therapeutics to Release Final Data from Phase 2 Study of Endoxifen Administered to Breast Cancer Patients Prior to Surgery at a Webinar at 8 am Pacific Time on June 9, 2021

June 6, 2021

Atossa Therapeutics Announces First Quarter 2021 Financial Results and Provides Corporate Update

May 13, 2021

Atossa Therapeutics Urges Shareholders to Vote on Proposals Ahead of its Annual Stockholder Meeting May 14, 2021 at 1: 00 PM Pacific Time

May 10, 2021

Atossa Therapeutics Announces Ovarian Cancer Patient has Begun Treatment with Oral Endoxifen under FDA’s Expanded Access Pathway

April 7, 2021

Atossa Therapeutics Announces Year End 2020 Financial Results and Provides Corporate Update

March 30, 2021

Atossa Therapeutics Announces Pricing of $50.0 Million Registered Direct Offering Priced At-The-Market

March 21, 2021

Atossa Therapeutics Announces Receipt of FDA Safe to Proceed Letter for Treatment of an Ovarian Cancer Patient with Oral Endoxifen Under Expanded Access Pathway

March 10, 2021

Atossa Therapeutics Announces Final Results from Phase 1 Clinical Study Showing Safety and Tolerability of AT-301 Nasal Spray Being Developed for COVID-19

February 24, 2021

← Newer news releases · Older news releases →

Calls

Decks

The 5 newest of 9 decks. Every deck is listed under its year.